decemb
new
coronaviru
caus
outbreak
pulmonari
diseas
citi
wuhan
capit
hubei
provinc
china
sinc
spread
global
viru
name
rna
genom
ident
sar
coronaviru
sarscov
virus
belong
clade
b
genu
betacoronaviru
diseas
caus
call
wherea
begin
outbreak
case
connect
huanan
seafood
anim
market
wuhan
effici
humantohuman
transmiss
led
exponenti
growth
number
case
march
world
health
organ
declar
outbreak
pandem
march
cumul
case
global
casefat
rate
one
best
character
drug
target
among
coronavirus
main
proteas
mpro
also
call
along
papainlik
proteas
enzym
essenti
process
polyprotein
translat
viral
rna
mpro
oper
less
cleavag
site
larg
polyprotein
replicas
kda
recognit
sequenc
site
ser
ala
gli
mark
cleavag
site
inhibit
activ
enzym
would
block
viral
replic
sinc
human
proteas
similar
cleavag
specif
known
inhibitor
unlik
toxic
previous
design
synthes
peptidomimet
broadspectrum
inhibitor
main
proteas
betacoronavirus
alphacoronavirus
well
proteas
enterovirus
best
compound
fig
show
picomolar
merscov
cell
well
low
micromolar
valu
sarscov
whole
rang
enterovirus
variou
cell
line
although
antivir
activ
seem
depend
great
extent
cell
type
use
experi
order
improv
halflif
compound
plasma
modifi
hide
amid
bond
within
pyridon
ring
fig
green
circl
expect
might
prevent
cellular
proteas
access
bond
cleav
increas
solubl
compound
plasma
reduc
bind
plasma
protein
replac
hydrophob
cinnamoyl
moieti
somewhat
less
hydrophob
boc
group
fig
red
circl
give
see
scheme
synthesi
order
examin
whether
introduc
pyridon
ring
compat
threedimension
structur
target
determin
crystal
structur
resolut
mpro
fig
threedimension
structur
highli
similar
sarscov
mpro
expect
sequenc
ident
see
fig
rm
deviat
two
freeenzym
structur
posit
comparison
mpro
structur
sarscov
mpro
pdb
entri
chymotrypsin
picornaviru
proteaselik
domain
ii
residu
respect
sixstrand
antiparallel
harbor
substratebind
site
domain
iii
residu
globular
cluster
five
helic
involv
regul
dimer
mpro
mainli
saltbridg
interact
one
protom
tight
dimer
form
mpro
contact
interfac
predominantli
domain
ii
molecul
residu
nfinger
molecul
b
two
molecul
orient
perpendicular
one
anoth
fig
dimer
enzym
necessari
catalyt
activ
nfinger
two
protom
interact
protom
therebi
help
shape
pocket
substratebind
site
reach
interact
site
nfinger
squeez
domain
ii
iii
parent
monom
domain
ii
monom
interestingli
sarscov
mpro
dimer
polar
interact
two
domain
iii
involv
hydrogen
bond
sidechain
hydroxyl
group
residu
protom
support
hydrophob
contact
sidechain
threonin
replac
alanin
indic
black
sphere
fig
isoleucin
leucin
see
fig
previous
shown
replac
alanin
residu
sarscov
mpro
lead
enhanc
catalyt
activ
proteas
concomit
slightli
closer
pack
two
domain
iii
dimer
one
anoth
accompani
chang
enzym
dynam
transmit
effect
mutat
catalyt
center
inde
replac
observ
mpro
also
allow
two
domain
iii
approach
littl
closer
distanc
atom
residu
molecul
b
sarscov
mpro
mpro
distanc
center
mass
two
domain
iii
shrink
howev
catalyt
effici
mpro
slightli
higher
kcatkm
sarscov
mpro
kcatkm
estim
kd
dimer
dissoci
two
enzym
determin
analyt
ultracentrifug
fig
use
crystal
structur
dock
suggest
pyridon
ring
might
steric
clash
sidechain
howev
previou
work
found
quit
flexibl
therefor
went
ahead
lead
plasma
halflif
compound
mice
increas
compar
hour
hour
invitro
kinet
plasma
solubl
improv
factor
thermodynam
solubl
factor
bind
mous
plasma
protein
reduc
mani
drug
plasma
protein
bind
howev
compar
structur
modif
led
loss
inhibitori
activ
main
proteas
well
proteas
enterovirus
design
broadspectrum
activ
cyclohexyl
moieti
intend
fill
pocket
enteroviru
pocket
betacoronaviru
mpro
see
fig
featur
substanti
plastic
enabl
adapt
shape
smaller
inhibitor
moieti
enhanc
antivir
activ
betacoronavirus
clade
b
sarscov
sacrif
goal
broadspectrum
activ
replac
cyclohexyl
moieti
smaller
cyclopropyl
fig
blue
circl
present
xray
crystal
structur
two
differ
crystal
form
resolut
complex
mpro
fig
one
structur
space
group
protom
mpro
dimer
bound
crystal
symmetri
ident
conform
space
group
two
protom
independ
free
adopt
differ
conform
inde
find
latter
crystal
structur
key
residu
adopt
inact
conform
protom
b
evidenc
distanc
lack
hbond
interact
moieti
inhibitor
even
though
compound
bound
mode
molecul
phenomenon
also
observ
sarscov
mpro
consist
halfsit
activ
describ
enzym
copi
inhibit
mpro
inhibitor
bind
shallow
substratebind
site
surfac
protom
domain
ii
fig
nucleophil
attack
catalyt
onto
group
inhibitor
thiohemiket
form
revers
reaction
clearli
reflect
electron
densiti
fig
inset
stereochemistri
chiral
moieti
copi
compound
structur
oxyanion
hydroxyl
group
thiohemiket
stabil
hydrogen
bond
wherea
amid
oxygen
accept
hydrogen
bond
mainchain
amid
partli
form
canon
oxyanion
hole
cystein
proteas
advantag
warhead
interact
catalyt
center
target
proteas
two
hydrogen
bond
interact
rather
one
warhead
aldehyd
michael
acceptor
moieti
design
glutamin
surrog
deepli
embed
pocket
proteas
lactam
nitrogen
donat
threecent
bifurc
hydrogen
bond
mainchain
oxygen
valu
structur
space
group
group
molecul
aspac
group
molecul
b
carboxyl
carbonyl
oxygen
accept
hbond
imidazol
cyclopropyl
methyl
moieti
fit
snugli
subsit
shrunk
compar
complex
compound
cyclohexyl
methyl
sarscov
mpro
pyridon
posit
inhibitor
occupi
space
normal
fill
substrat
main
chain
carbonyl
oxygen
accept
hydrogen
bond
mainchain
amid
residu
amid
donat
hbond
mainchain
oxygen
embed
within
pyridon
nitrogen
longer
donat
hydrogen
bond
protein
hbond
prevent
form
would
connect
nitrogen
sidechain
oxygen
two
atom
highlight
fig
howev
previou
crystal
structur
show
mainchain
amid
linear
make
hydrogen
bond
protein
case
interact
seem
critic
protect
boc
group
occupi
canon
site
proteas
contrast
protect
group
inhibitor
complex
sarscov
mpro
locat
near
fig
due
interact
latter
residu
move
outward
compar
structur
free
enzym
contact
explain
remov
boc
group
compound
fig
purpl
circl
weaken
inhibitori
potenc
compound
factor
interestingli
space
pyridon
ring
main
chain
residu
sidechain
smallest
distanc
fill
dmso
molecul
crystal
structur
water
molecul
structur
suggest
moieti
bulki
pyridon
may
accept
compound
inhibit
purifi
recombin
mpro
correspond
valu
inhibit
sarscov
mpro
merscov
mpro
respect
sarscov
replicon
rna
replic
inhibit
human
cell
infect
novel
coronaviru
observ
wherea
compound
lack
boc
group
almost
inact
fig
suggest
hydrophob
bulki
boc
group
necessari
cross
cellular
membran
even
hydrophob
moieti
might
advantag
although
may
lead
increas
plasma
protein
bind
observ
cinnamoylcontain
assess
absorpt
distribut
metabol
excret
adm
properti
pyridonecontain
first
investig
compound
metabol
stabil
mous
human
microsom
good
intrins
clearanc
rate
clintmous
protein
clinthuman
protein
mean
min
around
mous
human
respect
residu
compound
remain
metabol
stabl
pharmacokinet
studi
mice
use
subcutan
rout
mgkg
show
stay
plasma
hour
excret
via
urin
hour
cmax
determin
ngml
mean
resid
time
hour
although
seem
clear
rapidli
plasma
found
hour
ngg
tissu
lung
ngml
broncheoalveolar
lavag
fluid
balf
suggest
mainli
distribut
tissu
next
investig
pharmacokinet
properti
mice
use
subcutan
rout
well
mgkg
adm
paramet
similar
addit
bind
human
plasma
protein
found
cmax
determin
ngml
around
cmax
detect
although
dosag
approxim
lower
mean
resid
time
extend
hour
plasma
halflif
mice
hour
addit
show
less
rapid
clearanc
compar
tabl
pharmacokinet
studi
monitor
lung
tissu
level
hour
around
ngg
still
found
lung
tissu
lung
tropism
benefici
given
affect
lung
addit
subcutan
administr
nebul
use
inhal
devic
mgkg
hour
ngg
found
lung
tissu
inhal
toler
well
mice
show
advers
effect
suggest
way
direct
administr
compound
lung
would
possibl
given
favor
pharmacokinet
result
studi
provid
use
framework
develop
pyridonecontain
inhibitor
toward
anticoronavir
drug
